Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin–induced intestinal fluid secretion
Tonghui Ma, … , Luis J.V. Galietta, A.S. Verkman
Tonghui Ma, … , Luis J.V. Galietta, A.S. Verkman
Published December 1, 2002
Citation Information: J Clin Invest. 2002;110(11):1651-1658. https://doi.org/10.1172/JCI16112.
View: Text | PDF
Article Article has an altmetric score of 19

Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin–induced intestinal fluid secretion

  • Text
  • PDF
Abstract

Research Article

Authors

Tonghui Ma, Jay R. Thiagarajah, Hong Yang, Nitin D. Sonawane, Chiara Folli, Luis J.V. Galietta, A.S. Verkman

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Electrophysiological analysis of CFTR inhibition. (a) Left: CFTRinh-172 ...
Electrophysiological analysis of CFTR inhibition. (a) Left: CFTRinh-172 inhibition of short-circuit current (Isc) in permeabilized FRT cells expressing human CFTR. CFTR was stimulated by 100 μM CPT-cAMP. Right: Dose-inhibition data for CFTRinh-172 (circles) and glibenclamide (squares) (SE; n = 3 sets of experiments). (b) CFTRinh-172 inhibition of short-circuit current in primary culture of (nonpermeabilized) human bronchial epithelial cells. Inhibitor was added in apical bathing solution (left) or basolateral and then apical solutions (right). (c) Left: Whole-cell patch clamp of CFTR-expressing FRT cells showing membrane currents elicited at +80 mV (open circles) and –100 mV (filled circles). CFTR was stimulated by 5 μM forskolin followed by addition of 2 μM CFTRinh-172. The alternate stimulation was interrupted (I–III) for application of graded membrane potentials (middle). Right: Current-voltage relationships under basal conditions (control, open circles), after forskolin stimulation (filled circles), and following addition of 0.2 μM CFTRinh-172 giving approximately 50% inhibition (open triangles). Im, membrane current; Vm, membrane potential.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
Referenced in 34 patents
Referenced in 1 Wikipedia pages
51 readers on Mendeley
See more details